Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Completed · Phase 2
Conditions studied: Head and Neck Cancer
In brief
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with docetaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with docetaxel works in treating patients with recurrent or metastatic head and neck cancer.
Key facts
- Study ID
- NCT00425750
- Run by
- Vanderbilt-Ingram Cancer Center
- People needed
- 25
- Starts
- 2005-08-01
- Expected to finish
- 2009-06-01
- Last updated by the study team
- 2011-11-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jennie Stuart Medical Center — Hopkinsville, Kentucky, United States
- Purchase Cancer Group - Paducah — Paducah, Kentucky, United States
- Tennessee Plateau Oncology - Crossville — Crossville, Tennessee, United States
- West Tennessee Cancer Center at Jackson-Madison County General Hospital — Jackson, Tennessee, United States
- Baptist Regional Cancer Center at Baptist Riverside — Knoxville, Tennessee, United States
- MBCCOP - Meharry Medical College - Nashville — Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.